Pharmaceutical Research and Manufacturers of America. Biopharmaceutical research industry profile. www.phrma.org/sites/default/files/pdf/PhRMA%20Profile%202013.pdf. Published July 2013. Accessed September 2014.
European Federation of Pharmaceutical Industries and Associations. Pricing of medicines. www.efpia.eu/topics/industry-economy/pricing-of-medicines. Published 2014. Accessed December 2014.
Paul SM, Mytelka DS, Dunwiddie CT, et al. How to improve R&D productivity: the pharmaceutical industry’s grand challenge. Nat Rev Drug Discov. 2010;9:203–214.
Luce BR, Kramer JM, Goodman SN, et al. Rethinking randomized clinical trials for comparative effectiveness research: the need for transformational change. Ann Intern Med. 2009;151:206–209.
Djulbegovic B, Hozo I, Ioannidis JP. Improving the drug development process: more not less randomized trials. JAMA. 2014;311:355–356.
Fletcher B, Gheorghe A, Moore D, Wilson S, Damery S. Improving the recruitment activity of clinicians in randomised controlled trials: a systematic review. BMJ Open. 2012;2:e000496.
Petit-Zeman S. Why patients and clinicians should set priorities for cardiac researchers. Br J Card Nurs. 2012;7:95–97.
Stewart R, Oliver S. A Systematic Map of Studies of Patients’ and Clinicians’ Research Priorities. Oxford, UK: James Lind Alliance; 2008.
Mann H, Djulbegovic B. Comparator bias: why comparisons must address genuine uncertainties. In: JLL Bulletin 2012: Commentaries on the History of Treatment Evaluation. www.jameslindlibrary.org. Accessed September 2014.
Franson TR, Peay H. Benefit-risk assessments in rare disorders: the case for therapeutic development in Duchenne muscular dystrophy as the prototype for new approaches. www.phrma.org/catalyst/understanding-patient-perspective-critical-in-benefit-risk-assessment. Accessed September 2014.
Barber R, Beresford P, Boote J, Cooper C, Faulkner A. Evaluating the impact of public involvement on research: a prospective case study. Int J Consum Stud. 2011;35:609–615.
Staley K. Exploring Impact: Public Involvement in NHS, Public Health and Social Care Research. Eastleigh, UK: INVOLVE; 2009.
van Thiel G, Stolk P. Priority medicines for Europe and the world. A public health approach to innovation. Update 2013. Update on 2004 background paper, BP 8.5 patient and citizen involvement. www.who.int/medicines/areas/priority…/BP8_5Stakeholder.pdf. Accessed October 2014.
Department of Health and Human Services. Quick guide to health literacy fact sheet. Health literacy basics. http://health.gov/communication/literacy/quickguide/factsbasic.htm. Accessed December 2014.
Institute of Medicine. Roundtable on health literacy. http://www.iom.edu/Activities/PublicHealth/HealthLiteracy.aspx. Accessed December 2014.
Hale TM, Pathipati AS, Zan S, Jethwani K. Representation of health conditions on Facebook: content analysis and evaluation of user engagement. J Med Internet Res. 2014;16:e182.
Greene JA, Choudhry NK, Kilabuk E, et al. Online social networking by patients with diabetes: a qualitative evaluation of communication with Facebook. J Gen Intern Med. 2011;26:287–292.
Rozenblum R, Bates DW. Patient-centred healthcare, social media and the Internet: the perfect storm? BMJ Qual Saf. 2013;22:183–186.
European Patients’ Academy on Therapeutic Innovation. www.patientsacademy.eu. Accessed September 2014.
Frank L, Basch E, Selby JV; Patient-Centered Outcomes Research Institute. The PCORI perspective on patient-centered outcomes research. JAMA. 2014;312:1513–1514.
Manganiello M, Anderson M. Back to basics: HIV/AIDS advocacy as a model for catalyzing change. forces4quality.org/node/6968. Accessed September 2014.
Cystic Fibrosis Foundation. Annual report 2012. www.cff.org. Accessed September 2014.
Thornton H. Patient and public involvement in clinical trials. BMJ. 2008;336:903–904.
FasterCures. www.fastercures.org/. Accessed September 2014.
Prescription Drug User Fee Act, 21 USC, 1992.
Food and Drug Administration activities for patient participation in medical product discussions; establishment of a docket; request for comments. Fed Regist. 2014;79(213):65410–65411.
Food and Drug Administration. Enhancing benefit-risk assessment in regulatory decision-making. http://www.fda.gov/ForIndustry/UserFees/PrescriptionDrugUserFee/ucm326192.htm. Accessed December 2014.
Bere N. Overview of EMA’s interaction with patients and consumers organisations (2013). www.ema.europa.eu. Accessed September 2014.
European Medicines Agency. Annual report on European Medicines Agency’s interaction with patients, consumers, healthcare professionals and their organisations (2013). www.ema.europa.eu. Published 2015.
European Medicines Agency. Incorporating patients’ views during evaluation of benefit-risk by the EMA Scientific Committees. http://www.ema.europa.eu/docs/en_GB/document_library/Other/2014/09/WC500173508.pdf. Accessed December 2014.
European Medicines Agency. Patients to discuss benefit-risk evaluation of medicines with the Committee for Medicinal Products for Human Use (press release, September 26, 2014). http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2014/09/news_detail_002172.jsp&mid=WC0b01ac058004d5c1. Accessed December 2014.
Health Technology Assessment International. http://www.htai.org/about-htai/what-is-htai.html. Accessed December 2014.
Food and Drug Administration Safety and Innovation Act 2012. http://www.fda.gov/RegulatoryInformation/Legislation/FederalFoodDrugandCosmeticActFDCAct/SignificantAmendmentstotheFDCAct/FDASIA/default.htm. Accessed September 2014.
Public Law 112–144 (July 9, 2012). http://www.gpo.gov/fdsys/pkg/PLAW-112publ144/pdf/PLAW-112publ144.pdf. Accessed December 2014.
Food and Drug Administration. Guidance for industry. Collection of race and ethnicity data in clinical trials. http://www.fda.gov/downloads/RegulatoryInformation/Guidances/ucm126396.pdf. Published 2005. Accessed December 2014.
Food and Drug Administration. Collection, analysis, and availability of demographic subgroup data for FDA-approved medical products (August 2013). http://www.fda.gov/downloads/RegulatoryInformation/Legislation/FederalFoodDrugandCosmeticActFDCAct/SignificantAmendmentstotheFDCAct/FDASIA/UCM365544.pdf. Published 2013. Accessed December 2014.
Regulation (EC) No. 1901/2006 of the European Parliament and of the Council (December 12, 2006). http://ec.europa.eu/health/files/eudralex/vol-/reg_2006_1901/reg_2006_1901_en.pdf. Accessed December 2014.
European Medicines Agency. Pharmacovigilance legislation. www.ema.europa.eu/ema/. Published 2012. Accessed September 2014.
Eurobarometer Qualitative Study. Patient involvement—aggregate report 2012. ec.europa.eu/…/eurobaro_patient_involvement_2012_en.pdf. Accessed October 2014.
Health policy brief: patient engagement. Health Affairs. www.healthaffairs.org/healthpolicybriefs/. Published February 14, 2013. Accessed December 2014.
Longtin Y, Sax H, Leape LL, Sheridan SE, Donaldson L, Pittet D. Patient participation: current knowledge and applicability to patient safety. Mayo Clin Proc. 2010;85:53–62.
European Patients’ Forum manifesto for the 2014 European elections. Patient involvement = healthier Europe. Background briefing no. 4. www.eu-patient.eu/…/EPFManifesto_backgroundpaper4_NOV13.pdf. Published November 2013. Accessed October 2014.
National Health Council comments on Strategy for American Innovation request for information. www.nationalhealthcouncil.org/. Published September 23, 2014. Accessed October 2014.
National Working Group on Evidence-Based Health Care. The role of the patient/consumer in establishing a dynamic clinical research continuum: models of patient/consumer inclusion. http://www.evidencebasedhealthcare.org/images/download/W.G.PatientConsumerBklt2%288-6%29.pdf. Published August 2008.
Hirsch BR, Schulman KA. The economics of new drugs: can we afford to make progress in a common disease? Am Soc Clin Oncol Educ Book. 2013. doi:https://doi.org/10.1200/EdBook_AM.2013.33.e126.43.